Autopsy report · NCT03202004
GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis
Cause of deathFunding or business, also staffing, sites or logistics
“The decision not to progress the planned Phase 3 studies is a business decision based on the need to prioritise and focus resources within GSK.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 3
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Industry
- Conditions
- Psoriasis
- Interventions
- GSK2894512 1% cream; Vehicle cream
- Participants
- 0
Trials that died the same way
- Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis
“Study was prematurely discontinued due to GSK's change in prioritization for the portfolio and is not due to any safety concerns or regulatory interaction.” - PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase
“Business decision to focus on other studies. No safety concern.” - A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)
“Focus resources on a planned phase 2/3 study” - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
“Decision was made to not go forward with the study” - A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
“It has been made the strategic decision to terminate the study. This decision to terminate the study early is not being made for safety reasons.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.